Unraveling the PAF-AH/Lp-PLA2 controversy

Journal of Lipid Research

Volumn 55, Issue 9, 2014, Pages 1811-1814

  Stafforini, Diana M ^a,b   Zimmerman, Guy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

ANIMAL; HUMAN; PHYSIOLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; HUMANS;

EID: 84906875707     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E052886     Document Type: Note

References (45)

1. Marathe, G. K., C. Pandit, C. L. Lakshmikanth, V. H. Chaithra, S. P. Jacob, and C. J. D'Souza. 2014. To hydrolyse or not to hydrolyse: the dilemma of platelet activating factor acetylhydrolase (PAF-AH). J. Lipid Res. 55: 1847-1854.
2. McIntyre, T. M., S. M. Prescott, and D. M. Stafforini. 2009. The emerging roles of PAF acetylhydrolase. J. Lipid Res. 50(Suppl): S255-S259.
3. Stafforini, D. M. 2009. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc. Drugs Ther. 23: 73-83.
4. Rosenson, R. S., and D. M. Stafforini. 2012. Modulation of oxidative stress, infl ammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res. 53: 1767-1782.
5. Chen, C. H. 2004. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr. Opin. Lipidol. 15: 337-341.
6. Karabina, S. A., and E. Ninio. 2006. Plasma PAF-acetylhydrolase: an unfulfi lled promise? Biochim. Biophys. Acta. 1761: 1351-1358. (Pubitemid 44738700)
7. MacPhee, C. H., K. E. Moores, H. F. Boyd, D. Dhanak, R. J. Ife, C. A. Leach, D. S. Leake, K. J. Milliner, R. A. Patterson, K. E. Suckling, et al. 1999. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338: 479-487.
8. Blackie, J. A., J. C. Bloomer, M. J. Brown, H. Y. Cheng, B. Hammond, D. M. Hickey, R. J. Ife, C. A. Leach, V. A. Lewis, C. H. Macphee, et al. 2003. The identifi cation of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg. Med. Chem. Lett. 13: 1067-1070. (Pubitemid 36331801)
9. Daida, H., T. Iwase, S. Yagi, H. Ando, and H. Nakajima. 2013. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Circ. J. 77: 1518-1525.
10. García-García, H. M., R. M. Oemrawsingh, S. Brugaletta, P. Vranckx, J. Shannon, R. Davies, E. Boersma, and P. W. Serruys. 2012. Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes. Atherosclerosis. 225: 142-147.
11. Mohler, E. R., III, C. M. Ballantyne, M. H. Davidson, M. Hanefeld, L. M. Ruilope, J. L. Johnson, and A. Zalewski. 2008. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 51: 1632-1641. (Pubitemid 351635837)
12. Wang, W. Y., J. Zhang, W. Y. Wu, J. Li, Y. L. Ma, W. H. Chen, H. Yan, K. Wang, W. W. Xu, J. H. Shen, et al. 2011. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS ONE. 6: e23425.
13. Zhang, H., J. Y. Zhang, T. W. Sun, D. L. Shen, F. He, Y. H. Dang, and L. Li. 2013. Amelioration of atherosclerosis in apolipoprotein E-defi cient mice by inhibition of lipoprotein-associated phospholipase A2. Clin. Invest. Med. 36: E32.
14. Wilensky, R. L., Y. Shi, E. R. Mohler 3rd, D. Hamamdzic, M. E. Burgert, J. Li, A. Postle, R. S. Fenning, J. G. Bollinger, B. E. Hoffman, et al. 2008. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14: 1059-1066.
15. Serruys, P. W., H. M. Garcia-Garcia, P. Buszman, P. Erne, S. Verheye, M. Aschermann, H. Duckers, O. Bleie, D. Dudek, H. E. Botker, et al. 2008. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 118: 1172-1182.
16. O'Donoghue, M. L., E. Braunwald, H. D. White, P. Serruys, P. G. Steg, J. Hochman, A. P. Maggioni, C. Bode, D. Weaver, J. L. Johnson, et al. 2011. Study design and rationale for the Stabilization of Plaques using Darapladib- Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am. Heart J. 162: 613.e1-619.e1.
17. NCT01000727. Stabilization of Plaques using Darapladib Thrombolysis in Myocardial Infarction (SOLID-TIMI52, NCT01000727). Accessed 3 January 3, 2012, at http://clinicaltrials.gov.
18. White, H. 2010. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Curr. Opin. Cardiol. 25: 299-301.
19. White, H. D., C. Held, R. Stewart, E. Tarka, R. Brown, R. Y. Davies, A. Budaj, R. A. Harrington, P. G. Steg, D. Ardissino, et al. 2014. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370: 1702-1711.
20. White, H., C. Held, R. Stewart, D. Watson, R. Harrington, A. Budaj, P. G. Steg, C. P. Cannon, S. Krug-Gourley, J. Wittes, et al. 2010. Study design and rationale for the clinical outcomes of the STABILITY Trial (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) comparing darapladib versus placebo in patients with coronary heart disease. Am. Heart J. 160: 655-661.
21. Suckling, K. 2010. Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis. 212: 357-366.
22. Marathe, G. K., A. R. Silva, H. C. de Castro Faria Neto, L. W. Tjoelker, S. M. Prescott, G. A. Zimmerman, and T. M. McIntyre. 2001. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J. Lipid Res. 42: 1430-1437. (Pubitemid 34007673)
23. Schmitz, G., and K. Ruebsaamen. 2010. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 208: 10-18.
24. Karabina, S. A., T. A. Liapikos, G. Grekas, J. Goudevenos, and A. D. Tselepis. 1994. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim. Biophys. Acta. 1213: 34-38. (Pubitemid 24204562)
25. McCall, M. R., M. La Belle, T. M. Forte, R. M. Krauss, Y. Takanami, and D. L. Tribble. 1999. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. Biochim. Biophys. Acta. 1437: 23-36. (Pubitemid 29242900)
26. Tsimihodimos, V., S. A. Karabina, A. P. Tambaki, E. Bairaktari, J. A. Goudevenos, M. J. Chapman, M. Elisaf, and A. D. Tselepis. 2002. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol. 22: 306-311. (Pubitemid 34127044)
27. Ryu, S. K., Z. Mallat, J. Benessiano, A. Tedgui, A. G. Olsson, W. Bao, G. G. Schwartz, and S. Tsimikas. 2012. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 125: 757-766.
28. Ballantyne, C. M., R. C. Hoogeveen, H. Bang, J. Coresh, A. R. Folsom, G. Heiss, and A. R. Sharrett. 2004. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 109: 837-842. (Pubitemid 38252734)
29. Hoogeveen, R. C., and C. M. Ballantyne. 2005. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev. Mol. Diagn. 5: 9-14. (Pubitemid 40138763)
30. May, H. T., B. D. Horne, J. L. Anderson, R. L. Wolfert, J. B. Muhlestein, D. G. Renlund, J. L. Clarke, M. J. Kolek, T. L. Bair, R. R. Pearson, et al. 2006. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am. Heart J. 152: 997-1003. (Pubitemid 44632932)
31. Daniels, L. B., G. A. Laughlin, M. J. Sarno, R. Bettencourt, R. L. Wolfert, and E. Barrett-Connor. 2008. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol. 51: 913-919. (Pubitemid 351282456)
32. Kleber, M. E., R. L. Wolfert, G. D. De Moissl, T. B. Grammer, S. Dietz, B. R. Winkelmann, B. O. Boehm, and W. Marz. 2011. Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study). Clin. Lab. 57: 659-667.
33. Maiolino, G., L. Pedon, M. Cesari, A. C. Frigo, R. L. Wolfert, M. Barisa, L. Pagliani, G. Rossitto, T. M. Seccia, M. Zanchetta, et al. 2012. Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS ONE. 7: e48171.
34. Ridker, P. M., J. G. Macfadyen, R. L. Wolfert, and W. Koenig. 2012. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clinical chemistry.
35. Thompson, A., P. Gao, L. Orfei, S. Watson, E. Di Angelantonio, S. Kaptoge, C. Ballantyne, C. P. Cannon, M. Criqui, M. Cushman, et al. 2010. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 375: 1536-1544.
36. Prescott, S. M., G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre. 2000. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69: 419-445.
37. Prescott, S. M., G. A. Zimmerman, and T. M. McIntyre. 1990. Platelet-activating factor. J. Biol. Chem. 265: 17381-17384.
38. Shindou, H., D. Hishikawa, T. Harayama, M. Eto, and T. Shimizu. 2013. Generation of membrane diversity by lysophospholipid acyltransferases . J. Biochem. 154: 21-28.
39. Davis, B., G. Koster, L. J. Douet, M. Scigelova, G. Woffendin, J. M. Ward, A. Smith, J. Humphries, K. G. Burnand, C. H. Macphee, et al. 2008. Electrospray ionization mass spectrometry identifi es substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J. Biol. Chem. 283: 6428-6437.
40. Hu, M. M., J. Zhang, W. Y. Wang, W. Y. Wu, Y. L. Ma, W. H. Chen, and Y. P. Wang. 2011. The inhibition of lipoprotein-associated phospholipase A2 exerts benefi cial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol. Sin. 32: 1253-1258.
41. Shi, Y., A. Zalewski, C. H. Macphee, and M. Dawson. 2007. Selective inhibition of lipoprotein-associated phospholipase A2 attenuates markers of plaque vulnerability in humans. Circulation. 116 (Suppl) : II-08.
42. Carpenter, K. L., I. F. Dennis, I. R. Challis, D. P. Osborn, C. H. Macphee, D. S. Leake, M. J. Arends, and M. J. Mitchinson. 2001. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocytemacrophages. FEBS Lett. 505: 357-363. (Pubitemid 32905477)
43. Mullard, A. 2014. GSK's darapladib failures dim hopes for antiinflammatory heart drugs. Nat. Rev. Drug Discov. 13: 481-482.
44. Tjoelker, L. W., C. Wilder, C. Eberhardt, D. M. Stafforini, G. Dietsch, B. Schimpf, S. Hooper, H. Le Trong, L. S. Cousens, G. A. Zimmerman, et al. 1995. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 374: 549-553.
45. Liu, J., R. Chen, G. K. Marathe, M. Febbraio, W. Zou, and T. M. McIntyre. 2011. Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/PAF acetylhydrolase. Circ. Res. 108: 469-477.